IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.

Abstract excerpt

It is estimated that approximately 3% of the world population are chronically infected with HCV, as the annual incidence of HCV infection is approximately 3-4 million people. Despite all efforts made to eradicate the HCV infection, after the standard therapy (PegIFN and ribavirin for 48 weeks) only 40-50% of the HCV infected individuals with genotype 1 achieve sustained virological response (SVR). Since our goal...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Therapy, Combination
• Share to Interferon-alpha